GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
August 07, 2023 08:35 ET
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
GRI Bio (NASDAQ: GRI) to Present at Benzinga’s Virtual Biotech Conference
August 03, 2023 08:30 ET
|
GRI Bio, Inc.
- Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
July 24, 2023 09:00 ET
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...
GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023 08:45 ET
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
GRI Bio (NASDAQ: GRI) Bolsters Patent Portfolio
June 27, 2023 08:45 ET
|
GRI Bio, Inc.
- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
June 13, 2023 08:35 ET
|
GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
May 31, 2023 09:15 ET
|
Biostage, Inc.
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs...
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
May 22, 2023 08:45 ET
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...
Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
May 04, 2023 16:30 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...
Bioxytran Interview at the Emerging Growth Conference
May 01, 2023 08:00 ET
|
BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...